The global glioblastoma multiforme market is experiencing strong growth with launch of a novel drug for brain tumors by key players
The growing incidence of brain tumors is projected to foster the growth of the global glioblastoma multiforme market during the forecast period. As per the National Foundation for Cancer Research, GBM is the deadliest type of brain cancer, accounting for 45% of all malignant brain tumors. Furthermore, according to the article published by the National Brain Tumor Society, over 10% of people with brain tumors are at high risk of developing glioblastomas. Additionally, key players in the market are involved in joint ventures and partnerships to develop and commercialize novel drugs, in order to strengthen their business in the global glioblastoma multiforme market. For instance, in May 2017, DelMar Pharmaceuticals formalized the collaboration agreement with PRA Health Sciences to conduct phase 3 trials of VAL-083 for the treatment of recurrent GBM. North America is expected to dominate the global glioblastoma multiforme market and this is attributed to the increasing drug approv...